This is a Featured Course!
Exploiting Cytokine Biology and Strategies for Using Non-TNF Agents in Clinical Practice Training
- : Chatswood NSW 2067
Rheumatoid arthritis (RA) is a chronic, inflammatory disease affecting 1% of the population. If left untreated or undertreated, patients with RA can suffer from joint destruction as well as a wide array of debilitating extra-articular, systemic effects. This module explores the optimisation of the treatment of patients with RA, new and emerging therapies for patients with RA, including IL-6 inhibitors, and the effective use of these newer therapies in clinical practice.
Upon completion of this module the participant should be able to:
- Describe the role of cytokines, particularly IL-6, in the pathogenesis and treatment of RA
- Identify patients with RA in whom an IL-6 inhibitor, or other non-TNFi therapy, may be an appropriate strategy
- Describe new and emerging biologic therapies for RA
- Integrate strategies to address patient safety concerns and adverse events associated with TNF inhibitors
Disclosure of Conflicts of Interest
Roy Fleischmann, MD, MACR
Consultant/Advisor: Amgen Inc, AbbVie Inc, Bristol-Myers Squibb Company, Janssen Pharmaceutical Companies, Pfizer Inc, Sanofi-Regeneron, UCB Inc.
Grant/Research Support: Amgen Inc, AbbVie Inc, Bristol-Myers Squibb Company, Janssen Pharmaceutical Companies, Pfizer Inc, Sanofi-Regeneron, UCB Inc.
Speakers' Bureau: Pfizer Inc.
Peter Nash, MD
Has no financial relationships to disclose.
Christina M. Ohnsman, MD; Jessica Marshall, PhD; Lou Settembrino; Sandy Breslow; and Alison Kemp; hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Genzyme, a Sanofi Company and Regeneron Pharmaceuticals.
Jointly provided by the Elsevier Office of Continuing Medical Education, ASiM, In Vivo Academy Limited, and Reed Medical Education.